Original article
Release of leukotrienes in patients with bronchial asthma

https://doi.org/10.1016/0091-6749(88)91043-3Get rights and content

Abstract

To investigate whether leukotrienes (LTs) are released into the bronchial fluid of patients with symptomatic asthma, bronchial lavage was carried out in 17 patients with mild to severe asthma and nine healthy subjects without asthma. LTE4 was detected in 15 of the 17 patients with asthma with reverse-phase high-performance liquid chromatography. The identify of LTE4 was confirmed by ultraviolet spectrometry and by positive ion fast atom-bombardment mass spectrometry. LTD4 was found in two patients and 20-OH-LTB4 in 12 patients. No LTs were detectable in the lavage fluid from any of the healthy subjects without asthma. The finding of LTs in bronchial lavage fluid from the patients with asthma despite bronchodilator and/or corticosteroid therapy suggests that these compounds may be important in asthma. However, the presence of significant quantities of LTE4 in patients with mild asthma requiring only intermittent bronchodilator therapy for control and the lack of correlation between LTE4 and pulmonary function also suggests that other factors may be important in determining the net end organ response. The present study points to the importance of studying the whole spectrum of mediators that are released. Analysis of bronchial lavage fluid may be useful in determining the relative role of these mediators and the effect of pharmacologic intervention.

References (34)

  • SE Dahlen et al.

    Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with release of leukotrienes C4, D4, and E4

  • H Mita et al.

    Allergen induced histamine release and immunoreactive leukotriene C4 generation from leukocytes in mite-sensitive asthmatic patients

    Prostaglandins

    (1983)
  • S Lam et al.

    Effect of bronchial lavage volume on cellular and protein recovery

    Chest

    (1983)
  • H Salari et al.

    Studies on the release of leukotrienes and histamine by human lung parenchymal and bronchial fragments upon immunologic and nonimmunologic stimulation

    J Exp Med

    (1985)
  • H Salari

    Immunological and nonimmunological release of leukotrienes and histamine by guinea pig heart

    Immunology

    (1986)
  • SE Dahlen et al.

    Leukotrienes are potent constrictors of human bronchi

    Nature

    (1980)
  • M Griffin et al.

    Effects of leukotriene D on the airways in asthma

    N Engl J Med

    (1983)
  • Cited by (216)

    • Lipid Mediators and Lung Function

      2015, Comparative Biology of the Normal Lung: Second Edition
    • Airway smooth muscle in asthma: Linking contraction and mechanotransduction to disease pathogenesis and remodelling

      2014, Pulmonary Pharmacology and Therapeutics
      Citation Excerpt :

      Furthermore, in adult subjects with asthma, the presence of ASM tone reduces airway distensibility in vivo [57]. Thus in diseases such as asthma, where the airway may be exposed to sustained levels of contractile mediators [58–61], reduced degradation of ACh [62], and reduced production of the endogenous bronchodilator nitric oxide [63], the ASM may adopt a state of overall increased stiffness. The implications of mechanical remodelling as a consequence of ASM contraction and stiffening may be profound.

    • Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E<inf>4</inf> ligand

      2013, Journal of Biological Chemistry
      Citation Excerpt :

      The cys-LTs are mediators of bronchial asthma on the basis of their potent bronchoconstrictive activity via the CysLT1R in pharmacologic studies and the clinical effectiveness of CysLT1R antagonists (5, 6). LTE4, the most abundant cys-LT at sites of inflammation due to its stability (7, 8), was only a weak agonist for the CysLT1R and CysLT2R in studies with transfectants (3, 4), suggesting that it might lack agonist activity. In contrast, pretreatment with LTE4, but not LTC4 or LTD4, enhanced the response of guinea pig trachea (9) or human bronchial smooth muscle to histamine (10).

    • Mechanisms of intrinsic force in small human airways

      2012, Respiratory Physiology and Neurobiology
      Citation Excerpt :

      Of course, in airway diseases such as COPD and asthma enhanced airway luminal narrowing are caused by excessive shortening of ASM. The excessive shortening could result from exposure to spasmogens (Driver et al., 1993; Lam et al., 1988; Mattoli et al., 1991; Murray et al., 1986; Wenzel et al., 1991; White and Eiser, 1983), increased ASM mass (Hogg et al., 2004), increased myocyte contractility (Opazo Saez et al., 2000), reduced load on ASM (Bosse et al., 2007), or length adaptation of myocytes to passively or actively shortened lengths (McParland et al., 2005). However, another property of ASM which could affect nascent airway diameter is the force generation in the absence of concurrent neural or humeral (i.e., spasmogen) stimulation.

    View all citing articles on Scopus

    Supported by the British Columbia Health Care Research Foundation and the British Columbia Lung Association.

    1

    S. Lam, MD, UBC Respiratory Division, Vancouver General Hospital, 2775 Heather St., Vancouver, B.C. V5Z, 3J5, Canada.

    View full text